期刊文献+

环孢素胶丸的药代动力学和相对生物利用度 被引量:4

Pharmacokinetics and Relative Bioavailability of Cyclosporin Pearls in Healthy Volunteers
下载PDF
导出
摘要 采用高效液相色谱法进行环孢素胶丸的药代动力学和生物利用度研究,10名健康志愿者随机交叉单剂量po温州第二制药厂和瑞士Sandoz公司的环孢胶丸(200mg),其血药浓度-时间曲线均符合一级吸收的双室模型,温州产环孢素胶丸的主要药动学参数t1/2Kd=1.09±0.46h,t1/2α=0.34±0.15h,t1/2β=5.13±1.41h,tmax=1.19±0.19h,Cmax=878.2±167.2ng/ml,AUC=4127.7±854.1ng·h·ml-1,其相对生物利用度为(104.2±11.9)% The pharmacokinetics of cyclosporin from Wenzhou and Sandoz pearls was separately studied in healthy male volunteers after single oral administration at the dosage of 200 mg. Cyclosporin concentration in blood was determined by HPLC. The concentration time curve of cyclosporin from Wenzhou was fitted to two compartment model of the first order absorption. The pharmacokinetics parameters were estimated as follows: t 1/2Kd =1.09±0.46 h, t 1/2α =0.34±0.15 h, t 1/2β =5.13±1.41 h, t max =1.19±0.19 h, C max =878.2±167.2 ng/ml,AUC=4127. 7±854.1 ng·h·ml -1 . Relative bioavailability of Wenzhou pearls was 104.2%, compared with Sandoz pearls.
作者 王萍 陈西敬
出处 《中国药科大学学报》 CAS CSCD 北大核心 1996年第6期338-340,共3页 Journal of China Pharmaceutical University
关键词 环孢素 药代动力学 生物利用 Cyclosporin Pharmacokinetics Bioavailability HPLC
  • 相关文献

参考文献3

  • 1陈冠容.环孢素A临床应用的进展[J].中国医院药学杂志,1991,11(10):464-466. 被引量:2
  • 2陈秋潮.环孢素A临床药代动力学[J]新药与临床,1987(04).
  • 3张之荫.新型免疫抑制剂——环孢菌素A[J]抗生素,1986(05).

共引文献1

同被引文献23

  • 1陆晓和,赵仲坤,卓海通,储小曼,贺建国.环孢素A软膏的处方优选及其体外透皮试验[J].中国药学杂志,1994,29(8):473-475. 被引量:6
  • 2徐向阳,陈平,汪晓燕,宁静,张学伟,张和顺,马腾骧.高效液相色谱法及荧光偏振免疫法测定环孢素A血药浓度的比较[J].中国医院药学杂志,1995,15(6):243-245. 被引量:7
  • 3黄素英.局部应用环孢霉素A治疗巩膜炎的临床观察[J].广东医学,1996,17(2):89-90. 被引量:2
  • 4SLAM P, NORRIS R L, TAYLOR P J. A reliable high-performance liquid chromatography assay for high-throughputroutine cyclosporine a monitoring in whole blood [ J ] . Ther Drug Monit , 1993,15 ( 1 ) :65-68.
  • 5POIRIER J M, LEBOT J M, CHEYMOL G,et al. Cyclosporine in whole blood: Drug monitoring difficulities and presentation of an normal phase liquid chromatographic assay [ J ]. Ther Drug Monit, 1994,16 : 388-392.
  • 6Legendre C,Zuber J,Anglicheau D,et al.Immunosuppression inkidney transplantation[J].Ann Urol(Paris),2007,41(6):276-284.
  • 7Nashan B,Cole E,Levy G,et al.Clinical validation studies of Neoral C(2)monitoring:a review[J].Transplantation,2002,73(9 Suppl):S3-S11.
  • 8Tomaszewski JJ,Larson JA,Smaldone MC,et al.Management of bladder cancer following solid organ transplantation[J].Adv Urol,2011,2011:256985.
  • 9Kuypers DR.Influence of interactions between immunosuppressivedrugs on therapeutic drug monitoring[J].Ann Transplant,2008,13(3):11-18.
  • 10Zeng L,Blair EY,Nath CE,et al.Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood ormarrow and solid organ transplantation[J].Br J Clin Pharmacol,2010,70(4):567-579.

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部